2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Pathology, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Biological Processes, Pathogenesis, Immune Mechanism, Clinical Practice (Health Services and Quality), Practice Models, Quality Improvement, Diseases, Bleeding and Clotting, Bleeding Disorders, Platelet Disorders, Thrombocytopenias, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Lymphomas, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric
PAPER

1250 Platelet responses with combination therapy of fostamatinib and thrombopoietin receptor agonists in immune thrombocytopenia: An updated real-world analysis

David J Kuter, MD, DPhil, Maria Eva Mingot Castellano, MD2, Elizabeth Bowhay-Carnes, MD3, Bing Miu4, Aaron Sheppard, PhD5, Ralph Vincent Boccia, MD6
1 Hematology Division, Massachusetts General Hospital, Boston, Massachusetts, United States
2 Hematology Department, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla, Universidad de Sevilla, Sevilla, Spain
3 Division of Hematology-Oncology, Mays Cancer Center at UT Health MD Anderson, San Antonio, Texas, United States
4 Biometrics and Data Sciences, Rigel Pharmaceuticals, Inc., South San Francisco, California, United States
5 Medical Affairs, Rigel Pharmaceuticals, Inc., South San Francisco, California, United States
6 Center for Cancer and Blood Disorders, Bethesda, MD, and Clinical Associate Professor of Medicine, Georgetown University, Washington, DC, United States

Background

Immune thrombocytopenia (ITP) is a complex autoimmune disease characterized by both increased platelet destruction and impaired platelet production. Fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, and thrombopoietin receptor agonists (TPO-RAs) target complementary mechanisms involved in ITP pathogenesis by reducing platelet destruction and increasing platelet production, respectively. Real-world analyses have demonstrated clinically meaningful platelet responses in patients receiving fostamatinib plus TPO-RA combination therapy;1,2 however, the durability of these responses over time has not been fully characterized.

This analysis evaluated changes in platelet counts, achievement of platelet thresholds (≥30, ≥50, and ≥100 ×103/µL), sustained platelet threshold achievement, and platelet count patterns according to TPO-RA used in combination with fostamatinib over 12 months.

Methods

We conducted an updated analysis of a retrospective real-world study of patients with ITP enrolled in the RIGEL ONECARE® patient assistance program.2 Eligible patients had an ICD-10 code consistent with ITP, received fostamatinib for ≥30 days in combination with ≥1 dose of a TPO-RA (romiplostim, eltrombopag, or avatrombopag), received >3 months of fostamatinib supply with no treatment gap >60 days, had ≥1 platelet count before and after treatment initiation, and provided consent for data sharing. Baseline demographic, clinical, and platelet count data were collected through the program; follow-up platelet counts were recorded during routine nurse navigator contacts every 2 weeks or as agreed. Data were analyzed as available without a specified follow-up period. Platelet count thresholds of ≥30, ≥50, and ≥100 ×103/µL were evaluated over time. Sustained platelet response was defined as ≥2 consecutive platelet measurements at or above the specified threshold.

Results

Of 113 patients identified, 90 met eligibility criteria for inclusion in this analysis (concomitant therapy only). Median age was 71.0 years, 58% were female, median baseline platelet count was 23.8 ×103/µL, and romiplostim was the most commonly used TPO-RA (74%). In the overall analysis population, median platelet counts increased from 23.8 ×103/µL at baseline to 73.0 ×103/µL at Month 3, and remained elevated at 159.3 ×103/µL during Months 7–12. Similar platelet count trends were observed among patients who received fostamatinib in combination with romiplostim, eltrombopag, or avatrombopag.

Among patients with available platelet measurements, the proportions meeting the ≥30, ≥50, and ≥100 ×103/µL thresholds were generally higher during later follow-up periods. By months 7-12, 92.1% (35/38), 81.6% (31/38), and 71.1% (27/38) of patients, respectively, met these thresholds, compared with 45.6% (41/90), 33.3% (30/90), and 13.3% (12/90) at baseline. Sustained platelet responses were achieved by 74.4% (67/90; 95% confidence interval [CI], 64.2-83.1) of patients at ≥30 ×103/µL, 66.7% (60/90; 95% CI, 55.9-76.3) of patients at ≥50 ×103/µL, and 51.1% (46/90; 95% CI, 40.3-61.8) of patients at ≥100 ×103/µL.

Adverse events reported by patients during bi-weekly phone calls included diarrhea (23% of patients), increased blood pressure (18%), bruising/bleeding (12%), fatigue (8%), headache (5%), and thrombotic event (4%).

Conclusions

Combination therapy with fostamatinib and romiplostim, eltrombopag, or avatrombopag was associated with increased platelet counts and sustained achievement of clinically relevant platelet thresholds in patients with ITP, consistent with previous reports of clinically meaningful responses with fostamatinib/TPO-RA combination therapy.1 These findings support a treatment approach targeting multiple mechanisms of disease through the combination of fostamatinib and TPO-RAs and extend previous real-world analyses by characterizing longitudinal platelet responses and sustained platelet threshold attainment.

 

Mingot-Castellano ME, Lambert MP, Bowhay-Carnes E. Clin Med. 2026;15:1625. Bowhay-Carnes E, Kreychman Y, Buxman L, Todd L. 2024 (Supp1) 144: 5080.
David J Kuter, MD, DPhil: HUTCHMED - Research Funding; Sanofi - Research Funding; Fulcrum Therapeutics - Research Funding; Principia Biopharma - Research Funding; Novartis - Research Funding; Takeda - Research Funding; UCB - Consultancy (Includes expert testimony); Actelion - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Immunovant - Consultancy (Includes expert testimony); CVS Caremark - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Kyowa Kirin - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); BioCryst - Consultancy (Includes expert testimony); Principia Biopharma - Consultancy (Includes expert testimony); Daiichi Sankyo - Consultancy (Includes expert testimony); HUTCHMED - Consultancy (Includes expert testimony); UpToDate - Consultancy (Includes expert testimony); MSD - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Hengrui Pharmaceutical - Consultancy (Includes expert testimony); Genzyme - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Chugai Pharma - Consultancy (Includes expert testimony); Alpine Immune Sciences - Consultancy (Includes expert testimony); Verve - Consultancy (Includes expert testimony); Crico - Consultancy (Includes expert testimony); Platelet Disorder Support Association - Consultancy (Includes expert testimony); Alexion Pharmaceuticals - Consultancy (Includes expert testimony); Rigel - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony)